[go: up one dir, main page]

WO2004069177A3 - Methods for modulating an inflammatory response - Google Patents

Methods for modulating an inflammatory response Download PDF

Info

Publication number
WO2004069177A3
WO2004069177A3 PCT/US2004/002767 US2004002767W WO2004069177A3 WO 2004069177 A3 WO2004069177 A3 WO 2004069177A3 US 2004002767 W US2004002767 W US 2004002767W WO 2004069177 A3 WO2004069177 A3 WO 2004069177A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulating
methods
inflammatory response
wsx
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/002767
Other languages
French (fr)
Other versions
WO2004069177A2 (en
Inventor
Christopher Hunter
Alejandro Villarino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/002646 external-priority patent/WO2004069173A2/en
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Priority to CA2514641A priority Critical patent/CA2514641C/en
Priority to EP04707360A priority patent/EP1587483A4/en
Priority to JP2006503215A priority patent/JP4909069B2/en
Priority to AU2004209967A priority patent/AU2004209967B9/en
Priority to MXPA05008131A priority patent/MXPA05008131A/en
Publication of WO2004069177A2 publication Critical patent/WO2004069177A2/en
Anticipated expiration legal-status Critical
Publication of WO2004069177A3 publication Critical patent/WO2004069177A3/en
Priority to AU2009203080A priority patent/AU2009203080B9/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The inventive subject matter relates to novel methods for modulating an immune response in an animal, which comprises administering to said animal an effective amount of an agent that increases IL-27R/WSX-1 activity. Further, the inventive subject matter relates to pharmaceutical compositions comprising an effective amount of an agent that increases IL-27R/WSX-1 activity.
PCT/US2004/002767 2003-01-31 2004-02-02 Methods for modulating an inflammatory response Ceased WO2004069177A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA2514641A CA2514641C (en) 2003-01-31 2004-02-02 Methods for modulating an inflammatory response
EP04707360A EP1587483A4 (en) 2003-01-31 2004-02-02 METHODS FOR MODULATING AN INFLAMMATORY REACTION
JP2006503215A JP4909069B2 (en) 2003-01-31 2004-02-02 Methods for modulating inflammatory responses
AU2004209967A AU2004209967B9 (en) 2003-01-31 2004-02-02 Methods for modulating an inflammatory response
MXPA05008131A MXPA05008131A (en) 2003-01-31 2004-02-02 Methods for modulating an inflammatory response.
AU2009203080A AU2009203080B9 (en) 2003-01-31 2009-07-29 Methods for Modulating an Inflammatory Response

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US44449403P 2003-01-31 2003-01-31
US60/444,494 2003-01-31
US51907403P 2003-11-10 2003-11-10
US60/519,074 2003-11-10
PCT/US2004/002646 WO2004069173A2 (en) 2003-01-31 2004-01-30 Methods for modulating an inflammatory response
USPCT/US04/02646 2004-01-30

Publications (2)

Publication Number Publication Date
WO2004069177A2 WO2004069177A2 (en) 2004-08-19
WO2004069177A3 true WO2004069177A3 (en) 2006-01-12

Family

ID=32851399

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/002767 Ceased WO2004069177A2 (en) 2003-01-31 2004-02-02 Methods for modulating an inflammatory response

Country Status (2)

Country Link
MX (1) MXPA05008131A (en)
WO (1) WO2004069177A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4839434B2 (en) * 2005-03-14 2011-12-21 千葉県 Pharmaceutical formulation containing p28 molecule or gene thereof
US20100008917A1 (en) * 2006-08-25 2010-01-14 Nancy Hosken Treatment of aplastic anemia
WO2008025031A1 (en) * 2006-08-25 2008-02-28 Zymogenetics, Inc. Treatment of graft-versus-host disease
JP6175428B2 (en) 2011-06-01 2017-08-02 イントレクソン・アクトバイオテイクス・エヌブイＩｎｔｒｅｘｏｎ Ａｃｔｏｂｉｏｔｉｃｓ ＮＶ Bacterial polycistronic expression system
RU2760997C2 (en) 2016-01-14 2021-12-02 Интрексон Актобиотикс Н.В. Compositions and methods for treating type 1 diabetes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP1587483A4 *
SPRECHER C. ET AL: "Cloning and Characterization of a Novel Clas 1 Cytokine Receptor.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS., vol. 246, 1998, pages 82 - 90, XP002174914 *

Also Published As

Publication number Publication date
MXPA05008131A (en) 2005-10-05
WO2004069177A2 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
WO2004069173A3 (en) Methods for modulating an inflammatory response
WO2006031878A3 (en) Imidazoquinoline compounds
WO2006069241A3 (en) Methods for promoting oral health in animals
WO2005004818A3 (en) Heterocyclic compounds and their use as anticancer agents
EP2592073A3 (en) Human protein tyrosine phosphatase inhibitors and their use
WO2007120528A3 (en) Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2006002976A3 (en) Canine osteoarthritis diet formulation
WO2005123116A3 (en) Compositions and methods for treating or preventing oxalate-related disease
WO2005003172A3 (en) Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2007070052A3 (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
ZA200705750B (en) Compositions and methods for stabilizing active pharmaceutical ingredients
WO2006012527A8 (en) Bivalent linkers and conjugates thereof
WO2008087367A3 (en) Substituted (phenylthiazolyl)-phenyl-propan-1-one and (phenyloxazodyl)-phenyl-propan-1-one derivatives, preparations and uses of same
CA2672094C (en) Methods and apparatus for identifying subject matter in view data
WO2007092065A3 (en) Compounds and compositions as lxr modulators
MXPA05000765A (en) 5-aryltetrazole compounds, compositions thereof, and uses therefor.
EP2279726A3 (en) Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
WO2005077122A3 (en) Compounds and compositions as lxr modulators
WO2008051862A3 (en) Immunopotentiating compositions comprising beta-1,3/1,6-d-glucan and uses thereof
WO2004069177A3 (en) Methods for modulating an inflammatory response
WO2005077124A3 (en) Compounds and compositions as lxr modulators
FR2865938B1 (en) SOLID DELAY FORMULATION COMPRISING TRIPTORELINE ACETATE
WO2005123113A3 (en) Interferon compositions and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/008131

Country of ref document: MX

Ref document number: 2514641

Country of ref document: CA

Ref document number: 2004707360

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006503215

Country of ref document: JP

Ref document number: 2004209967

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004209967

Country of ref document: AU

Date of ref document: 20040202

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004209967

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004707360

Country of ref document: EP